Developing RNA therapeutics for rare neurodevelopmental disorders

Active Project Grant Awarded Last action

Award ID
R42HD111138
Recipient
Awarding agency
Obligated
$4,560,681

Award facts

Completion date 94% complete
Originally
Place of performance
New York, NY 10032, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
Developing RNA therapeutics for rare neurodevelopmental disorders monogenic diseases caused by mutations in single genes are individually rare, but collectively common affecting 10% of the world population. Many of these diseases are disabling or even life threatening with no available treatment. The underlying molecular mechanisms vary. Both loss of gene function and gain of toxic or dominant negative effects can lead to pathology, and modification of gene expression could be disease modifying. Dayi therapeutics, INC is a spin-out of columbia university medical center that has the goal of advancing precisely targeted RNA therapeutics for the treatment of rare monogenic diseases, especially neurological disorders affecting the brain and behavior. Using a proprietary target discovery platform developed by our academic CO- founders, we have prioritized a list of target genes causing severe neurodevelopmental disorders with tremendous unmet medical needs. These target genes are in general difficult to target with current approaches but are druggable with our unique technology to identify endogenous, naturally occurring gene regulatory regions that can be targeted by different therapeutic modalities including antisense oligonucleotides (asos). In this proposal, we aim to develop the first therapeutic for a severe developmental and intellectual disability syndrome by restoring gene expression and protein function using an ASO. The feasibility of our approach is supported by compelling preliminary data. We propose to perform a systematic ASO drug screen to identify the most effective asos as drug lead and then conduct a series of pre-clinical studies to validate their efficacy in correcting the molecular, cellular and behavioral deficits caused by the mutation using patient-derived ipscs, brain organoids and mouse models. Asos are an established therapeutic agent with the advantage of high target specificity, clear mode of action, and accelerated timeline from drug discovery to clinical deployment. If successful, this study will provide the critical first step to develop a novel ASO therapeutic to fulfill unmet medical needs and potentially also serve as proof of principle for treatment of neurodevelopmental disorders caused by mutations in a wide range of genes.

Transactions

Action Obligated Date
Amendment $845,187
Amendment $0
Amendment $0
Amendment $0
Amendment $853,987
Amendment $853,987
Amendment $853,987
Amendment $853,987
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Original award $299,546
Show all 14

Subawards

Subrecipient Amount Awarded
The Trustees Of Columbia University In The City Of New York Dr. Yueqing Peng at Columbia University will closely collaborate with Dr. Lotti and the team at DAYI to coordinate the efforts in developing the therapeutic for… $256,620
The Trustees Of Columbia University In The City Of New York SCOPE OF WORK STATEMENT Dr. Chaolin Zhang is an Associate Professor (with tenure) in the Department of Systems Biology, Department of Biochemistry and Molecular… $88,308

Quick answers

Who received award R42HD111138?

R42HD111138 was awarded to Dayi Therapeutics Inc. by National Institute of Child Health and Human Development (National Institutes of Health) on May 1, 2023.

How much is award R42HD111138 worth?

$4,560,681 has been obligated on R42HD111138.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login